共 22 条
- [21] Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT). JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
- [22] EFFICACY ANALYSIS FOR MOLECULAR SUBGROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC) JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S901 - S902